Trial Profile
A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure/Severe Acute Liver Injury
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ornithine phenylacetate (Primary)
- Indications Liver failure; Liver injury
- Focus Adverse reactions
- Acronyms STOP-ALF
- 10 Jan 2018 Status changed from active, no longer recruiting to completed.
- 24 Oct 2016 Results published in Ocera Therapeutics media release.
- 24 Oct 2016 According to Ocera Therapeutics media release, clinical data from this study will be presented in the late-breaking poster session at The Liver Meeting 2016, the 67th Annual Meeting of the American Association for the Study of Liver Disease (AASLD).